Insulin-like growth factor-II

Drug Profile

Insulin-like growth factor-II

Alternative Names: Somatomedin-2

Latest Information Update: 21 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; KabiGen; Karolinska Institute
  • Class Antihyperglycaemics; Antineoplastics; Growth factors; Peptides
  • Mechanism of Action Insulin-like growth factor II stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 08 Oct 2001 No-Development-Reported for Diabetes mellitus (Unknown route)
  • 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 13 Oct 1995 Eli Lilly is developing somatomedin-2 in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top